Parkman Healthcare Partners LLC Sells 92,915 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

Parkman Healthcare Partners LLC decreased its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 20.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 352,481 shares of the company's stock after selling 92,915 shares during the period. Parkman Healthcare Partners LLC owned approximately 0.51% of Bicycle Therapeutics worth $4,935,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in BCYC. Barclays PLC raised its holdings in shares of Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after acquiring an additional 2,345 shares during the last quarter. Avior Wealth Management LLC bought a new position in shares of Bicycle Therapeutics during the 4th quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after buying an additional 2,191 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after buying an additional 1,782 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Bicycle Therapeutics by 18.9% during the 4th quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock worth $336,000 after buying an additional 3,811 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BCYC shares. Morgan Stanley set a $17.00 price target on Bicycle Therapeutics and gave the stock an "equal weight" rating in a report on Monday, May 5th. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Royal Bank of Canada dropped their price objective on Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. B. Riley dropped their price objective on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Finally, Needham & Company LLC reissued a "buy" rating and set a $29.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $25.00.

Bicycle Therapeutics Price Performance

NASDAQ BCYC traded up $0.55 during trading hours on Monday, reaching $8.65. 180,855 shares of the stock traded hands, compared to its average volume of 403,778. The stock has a 50 day simple moving average of $8.24 and a two-hundred day simple moving average of $13.12. Bicycle Therapeutics plc has a 1 year low of $6.10 and a 1 year high of $28.67. The company has a market cap of $598.70 million, a price-to-earnings ratio of -2.62 and a beta of 1.60.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The firm had revenue of $9.98 million for the quarter, compared to analysts' expectations of $8.67 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. On average, sell-side analysts forecast that Bicycle Therapeutics plc will post -3.06 EPS for the current fiscal year.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.